These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

619 related articles for article (PubMed ID: 21040950)

  • 21. Influence of epidermal growth factor receptor (EGFR) gene mutations on the expression of EGFR, phosphoryl-Akt, and phosphoryl-MAPK, and on the prognosis of patients with non-small cell lung cancer.
    Sonobe M; Nakagawa M; Takenaka K; Katakura H; Adachi M; Yanagihara K; Otake Y; Wada H; Tanaka F
    J Surg Oncol; 2007 Jan; 95(1):63-9. PubMed ID: 17192868
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical and molecular analysis of PI3K/AKT/mTOR pathway in esophageal carcinoma.
    Tasioudi KE; Sakellariou S; Levidou G; Theodorou D; Michalopoulos NV; Patsouris E; Korkolopoulou P; Saetta AA
    APMIS; 2015 Aug; 123(8):639-47. PubMed ID: 25912437
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comprehensive immunohistochemical approach of AKT/mTOR pathway and p-STAT3 in mycosis fungoides.
    Levidou G; Siakantaris M; Papadaki T; Papadavid E; Vassilakopoulos TP; Angelopoulou MK; Marinos L; Nikolaou V; Economidi A; Antoniou C; Patsouris E; Korkolopoulou P
    J Am Acad Dermatol; 2013 Sep; 69(3):375-84. PubMed ID: 23685026
    [TBL] [Abstract][Full Text] [Related]  

  • 24. EGF receptor transactivation mediates ANG II-stimulated mitogenesis in intestinal epithelial cells through the PI3-kinase/Akt/mTOR/p70S6K1 signaling pathway.
    Chiu T; Santiskulvong C; Rozengurt E
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G182-94. PubMed ID: 15358595
    [TBL] [Abstract][Full Text] [Related]  

  • 25. EGFR-dependent and independent activation of Akt/mTOR cascade in bone and soft tissue tumors.
    Dobashi Y; Suzuki S; Sato E; Hamada Y; Yanagawa T; Ooi A
    Mod Pathol; 2009 Oct; 22(10):1328-40. PubMed ID: 19648884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways.
    Han S; Khuri FR; Roman J
    Cancer Res; 2006 Jan; 66(1):315-23. PubMed ID: 16397245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Activation of the mammalian target of rapamycin signalling pathway in epidermal tumours and its correlation with cyclin-dependent kinase 2.
    Chen SJ; Nakahara T; Takahara M; Kido M; Dugu L; Uchi H; Takeuchi S; Tu YT; Moroi Y; Furue M
    Br J Dermatol; 2009 Feb; 160(2):442-5. PubMed ID: 19016696
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lovastatin inhibits EGFR dimerization and AKT activation in squamous cell carcinoma cells: potential regulation by targeting rho proteins.
    Zhao TT; Le Francois BG; Goss G; Ding K; Bradbury PA; Dimitroulakos J
    Oncogene; 2010 Aug; 29(33):4682-92. PubMed ID: 20562912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
    Markova B; Albers C; Breitenbuecher F; Melo JV; Brümmendorf TH; Heidel F; Lipka D; Duyster J; Huber C; Fischer T
    Oncogene; 2010 Feb; 29(5):739-51. PubMed ID: 19881535
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Involvement of epidermal growth factor receptor and downstream molecules in bone and soft tissue tumors.
    Dobashi Y; Suzuki S; Sugawara H; Ooi A
    Hum Pathol; 2007 Jun; 38(6):914-25. PubMed ID: 17376509
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
    Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
    Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
    Gadgeel SM; Wozniak A
    Clin Lung Cancer; 2013 Jul; 14(4):322-32. PubMed ID: 23332287
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Estrogen-induced activation of mammalian target of rapamycin is mediated via tuberin and the small GTPase Ras homologue enriched in brain.
    Yu J; Henske EP
    Cancer Res; 2006 Oct; 66(19):9461-6. PubMed ID: 17018601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activation of the AKT and STAT3 pathways and prolonged survival by a mutant EGFR in human lung cancer cells.
    Akca H; Tani M; Hishida T; Matsumoto S; Yokota J
    Lung Cancer; 2006 Oct; 54(1):25-33. PubMed ID: 16872715
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Impact of the integrin signaling adaptor protein NEDD9 on prognosis and metastatic behavior of human lung cancer.
    Kondo S; Iwata S; Yamada T; Inoue Y; Ichihara H; Kichikawa Y; Katayose T; Souta-Kuribara A; Yamazaki H; Hosono O; Kawasaki H; Tanaka H; Hayashi Y; Sakamoto M; Kamiya K; Dang NH; Morimoto C
    Clin Cancer Res; 2012 Nov; 18(22):6326-38. PubMed ID: 23037767
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A detailed immunohistochemical analysis of the PI3K/AKT/mTOR pathway in lung cancer: correlation with PIK3CA, AKT1, K-RAS or PTEN mutational status and clinicopathological features.
    Trigka EA; Levidou G; Saetta AA; Chatziandreou I; Tomos P; Thalassinos N; Anastasiou N; Spartalis E; Kavantzas N; Patsouris E; Korkolopoulou P
    Oncol Rep; 2013 Aug; 30(2):623-36. PubMed ID: 23728071
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IGF-1-stimulated protein synthesis in oligodendrocyte progenitors requires PI3K/mTOR/Akt and MEK/ERK pathways.
    Bibollet-Bahena O; Almazan G
    J Neurochem; 2009 Jun; 109(5):1440-51. PubMed ID: 19453943
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Akt/mTOR/4E-BP1 pathway signal activation and mutations of PIK3CA in Merkel cell polyomavirus-positive and Merkel cell polyomavirus-negative carcinomas.
    Iwasaki T; Matsushita M; Nonaka D; Kuwamoto S; Kato M; Murakami I; Nagata K; Nakajima H; Sano S; Hayashi K
    Hum Pathol; 2015 Feb; 46(2):210-6. PubMed ID: 25466966
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Differential ErbB receptor expression and intracellular signaling activity in lung adenocarcinomas and squamous cell carcinomas.
    López-Malpartida AV; Ludeña MD; Varela G; García Pichel J
    Lung Cancer; 2009 Jul; 65(1):25-33. PubMed ID: 19046792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.